BioSpace

Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset

Astellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.

By BioSpace

1 min read
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights